PROCEPT BioRobotics's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 98.75.
PROCEPT BioRobotics's Days Inventory for the
three
months ended in Mar. 2026 was 231.73.
PROCEPT BioRobotics's Days Payable for the
three
months ended in Mar. 2026 was 56.49.
Therefore, PROCEPT BioRobotics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 273.99.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
PROCEPT BioRobotics Cash Conversion Cycle Related Terms
PROCEPT BioRobotics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs ALMR, AHCO, ENOV: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
PROCEPT BioRobotics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Cash Conversion Cycle of 273.99 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Cash Conversion Cycle too high?
PROCEPT BioRobotics' current Cash Conversion Cycle is 273.99. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. PROCEPT BioRobotics' value of 273.99 is 74.6% above this industry median. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Cash Conversion Cycle compare to ALMR and AHCO?
PROCEPT BioRobotics' Cash Conversion Cycle of 273.99 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. PROCEPT BioRobotics' value of 273.99 is 74.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Cash Conversion Cycle of 273.99 is 74.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Cash Conversion Cycle is 273.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Cash Conversion Cycle is 273.99 and 74.6% above the Medical Devices & Instruments industry median of 156.96. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Cash Conversion Cycle is 273.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Cash Conversion Cycle: 273.99
GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
Industry Position: 74.6% above the Medical Devices & Instruments median
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
